Menu
Recruiting NCT06324942

Analgesic Efficacy of Surgeon-administered Transversus Abdominis Plane Blocks for Caesarean Section.

No phase Interventional Cesarean Section Complications Pain, Postoperative

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Surgeon-administered Transversus Abdominis Plane Block 0.25% bupivicaine 0.25 mL/kg.
Who it may be relevant to
Registry conditions: Cesarean Section Complications, Pain, Postoperative. Basic parameters: from 18 years · Female.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Canada
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

The purpose of this research study is to evaluate whether or not adding a Transversus Abdominis Plane Block (TAP block) improves pain control for patients having a cesarean section. A TAP block is a type of nerve block where at the end of the surgery an injection of a long acting local anesthetic is made into the abdominal wall. In studies in patient's having other abdominal surgeries this has reduced the amount of narcotics patients need for pain control. This may also led to patients being more active after surgery and maybe spending less time in hospital.

Detailed description

Randomized clinical trial of Transversus Abdominis Plane Block (TAP block) at Cesarean Section.

Interventions

  • Other Surgeon-administered Transversus Abdominis Plane Block 0.25% bupivicaine 0.25 mL/kg
    Surgeon-administered Transversus Abdominis Plane Block

Primary outcome measures

  • Post operative Pain [Time frame: 12 hours post op]
Secondary outcome measures (3)
  • Time to first request for rescue analgesia in hours [Time frame: 48 hours post op]
  • Post operative Opioid use [Time frame: up to 48 hours post op.]
  • Time from surgery to discharge from hospital [Time frame: Up to discharge from hospital, usually 1-3 days]

Eligibility criteria

Inclusion criteria

  • ASA status II to III
  • All patients undergoing elective CS under regional anesthesia at any gestational age.

Exclusion criteria

  • \- Known drug allergy to local anesthetics
  • Planned general anesthetic
  • NSAID use contraindicated post partum
  • Chronic pain disorder or chronic narcotic use/dependence
  • Planned vertical abdominal incision
  • Planned Cesarean Hysterectomy.
  • Placenta Previa or suspected Placenta Accreta

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Double blind
Primary purpose
Treatment

Study locations

Canada · 1 center
  • University of Calgary — Calgary

Identifiers

NCT: NCT06324942 · REB24-0349

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗